Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
- PMID: 38418343
- DOI: 10.1016/j.eururo.2024.01.007
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
Abstract
Background and objective: In comparison to chemotherapy, enfortumab vedotin (EV) prolonged overall survival in patients with previously treated advanced urothelial carcinoma in EV-301. The objective of the present study was to assess patient experiences of EV versus chemotherapy using patient-reported outcome (PRO) analysis of health-related quality of life (HRQoL).
Methods: For patients in the phase 3 EV-301 trial randomized to EV or chemotherapy we assessed responses to the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline, weekly for the first 12 wk, and then every 12 wk until discontinuation. We analyzed the QLQ-C30 change from baseline to week 12, the confirmed improvement rate, and the time to improvement or deterioration.
Key findings and limitations: Baseline PRO compliance rates were 91% for the EV arm (n = 301) and 89% for the chemotherapy arm (n = 307); the corresponding average rates from baseline to week 12 were 70% and 67%. Patients receiving EV versus chemotherapy had reduced pain (difference in change from baseline to week 12: -5.7, 95% confidence interval [CI] -10.8 to -0.7; p = 0.027) and worsening appetite loss (7.3, 95% CI 0.90-13.69; p = 0.026). Larger proportions of patients in the EV arm reported HRQoL improvement from baseline than in the chemotherapy arm; the odds of a confirmed improvement across ten QLQ-C30 function/symptom scales were 1.67 to 2.76 times higher for EV than for chemotherapy. Patients in the EV arm had a shorter time to first confirmed improvement in global health status (GHS)/QoL, fatigue, pain, and physical, role, emotional, and social functioning (all p < 0.05). EV delayed the time to first confirmed deterioration in GHS/QoL (p = 0.027), but worsening appetite loss occurred earlier (p = 0.009) in comparison to chemotherapy.
Conclusions and clinical implications: HRQoL with EV was maintained, and deterioration in HRQoL was delayed with EV in comparison to chemotherapy. Better results with EV were reported for some scales, with the greatest difference observed for pain. These findings reinforce the EV safety and efficacy outcomes and benefits observed in EV-301.
Patient summary: Patients with previously treated advanced cancer of the urinary tract receiving the drug enfortumab vedotin maintained their HRQoL in comparison to patients treated with chemotherapy. The EV-301 trial is registered on ClinicalTrials.gov as NCT03474107 and on EudraCT as 2017-003344-21.
Keywords: Antineoplastic agents; Cancer pain; Immunoconjugates; Patient-reported outcome measures; Urinary bladder neoplasms.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Comment in
-
HRQoL in patients receiving EV versus chemotherapy.Nat Rev Urol. 2024 May;21(5):257. doi: 10.1038/s41585-024-00882-y. Nat Rev Urol. 2024. PMID: 38627550 No abstract available.
Similar articles
-
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
-
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.Urol Oncol. 2022 Oct;40(10):413-423. doi: 10.1016/j.urolonc.2022.07.006. Epub 2022 Aug 13. Urol Oncol. 2022. PMID: 35973928 Review.
-
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.Expert Rev Anticancer Ther. 2022 May;22(5):449-455. doi: 10.1080/14737140.2022.2069563. Epub 2022 Apr 26. Expert Rev Anticancer Ther. 2022. PMID: 35466857 Review.
-
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.Eur Urol. 2022 May;81(5):515-522. doi: 10.1016/j.eururo.2022.01.032. Epub 2022 Feb 12. Eur Urol. 2022. PMID: 35168844 Free PMC article. Clinical Trial.
-
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).BMC Urol. 2020 Nov 7;20(1):181. doi: 10.1186/s12894-020-00752-w. BMC Urol. 2020. PMID: 33160359 Free PMC article. Clinical Trial.
Cited by
-
HRQoL in patients receiving EV versus chemotherapy.Nat Rev Urol. 2024 May;21(5):257. doi: 10.1038/s41585-024-00882-y. Nat Rev Urol. 2024. PMID: 38627550 No abstract available.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources